Amycretin helped patients lose over 24% of their weight, compared with an average of about 17% for Wegovy.

A federal court ruled in Mylan's favor, finding no infringement of Novo's patent tied to Wegovy, rejecting direct, ...

Novo declined interview requests, citing its quiet period ahead of the third-quarter results. Under Pressure. If CagriSema meets Novo’s self-set 25% weight-loss bar, it will give the Danish ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Telehealth company Hims & Hers is facing a growing number of U.S. investor lawsuits after Novo Nordisk's decision last month ...

Novo Nordisk sees solid Q1 results, major GLP-1 growth potential, and limited downside despite guidance cut and rising risks.

Novo’s New Obesity Drug Is Targeting the Most Dramatic Weight Loss Yet. The drugmaker hopes to show CagriSema leads to at least 25% weight loss, without increased side effects.

Data from an early stage clinical trial suggests Novo Nordisk’s new weight loss pill amycretin could produce greater and more rapid weight loss than its popular obesity injection Wegovy.